Quick Summary
Covering the latest research from top Wall Street investment banks

Goldman Sachs sees a clearer growth and cash flow improvement path after Masco's Investor Day

Institution
Goldman Sachs
Date
2026-05-18
Authors
Susan Maklari, Charles Perron-Piche, CFA, Rhea Bhatia, Galilee Best
Company
Masco Corp.
Ticker
MAS.US
Industry
Building Products & Equipment
Rating
Buy
BullishHigh confidenceThe report argues that at its Investor Day, Masco presented clear three-year targets for growth, margins, and EPS, and that innovation, digitalization, efficiency improvement, and capital returns across its plumbing, paint, and wellness businesses should support roughly 10% three-year EPS CAGR.
AuthorsSusan Maklari, Charles Perron-Piche, CFA, Rhea Bhatia, Galilee Best
Target price$90.00
CoverageUnited States
Asset classesEquity
Business segmentsPlumbing、Decorative Architectural Products、Wellness
Research firm divisions/subsidiariesGoldman Sachs(Other)

AI summary card

Goldman Sachs sees a clearer growth and cash flow improvement path after Masco's Investor Day

Goldman Sachs reiterated its Buy rating on Masco and its 12-month $90 target price, believing the company can deliver steady revenue, margin, and EPS growth through 2028 by refocusing its core businesses, innovation, digitalization, and operational efficiency.

Rating: Buy; 12-month target price: $90.00; current price: $67.48; implied upside: 33.4%.
Buy RatingInvestor DayBuilding ProductsOperational EfficiencyCash FlowHousing RecoveryShareholder Returns
  • Management targets revenue of $8.1 billion to $8.4 billion by 2028, implying 3% to 4% annual growth, driven primarily by product innovation, brand strength, and global commercial opportunities.
  • Adjusted EBIT margin is targeted to exceed 18% by 2028, supported by volume and mix improvement, cost savings, the Masco Operating System, and price/cost improvement.
  • The company expects adjusted EPS to grow at a roughly 10% three-year CAGR through 2028, assuming a modest housing-market recovery.
  • Capital allocation prioritizes organic growth, maintaining gross debt/EBITDA below 2.5x, an approximately 30% dividend payout ratio, and enhancing shareholder returns through buybacks or tuck-in M&A.
  • Key risks include intensified competition, company-specific initiatives falling short of expectations, rising raw material costs that cannot be passed through, and uncertainty in international production and sales.

Report interpretation

Overview

This report is Goldman Sachs' company research commentary on Masco Corp.'s Investor Day. The core view is that Masco outlined a more focused growth framework, and that innovation, channel expansion, technology and data applications, and improved operating efficiency across its plumbing, paint/decorative building products, and wellness businesses should support growth in revenue, margins, cash flow, and EPS over the next three years. Goldman Sachs maintained its Buy rating and a 12-month target price of $90.

Core views

Goldman Sachs believes Masco is capable of delivering earnings growth above the industry average. On the revenue side, the company targets $8.1 billion to $8.4 billion by 2028, implying 3% to 4% annual growth and outpacing low-single-digit market growth. On the margin side, adjusted EBIT margin is targeted to exceed 18%. On the EPS side, adjusted EPS is expected to compound at roughly 10% annually over the three years through 2028. The report emphasizes that growth is not dependent solely on macro recovery, but also on company-specific initiatives, including the strength of core brands, an innovative product pipeline, digital customer experience, commercial channel expansion, manufacturing and distribution network optimization, and disciplined capital allocation.

Analysis framework

The report mainly analyzes management's Investor Day targets, Goldman Sachs forecasts, valuation multiples, growth opportunities by segment, and risk assessment. Goldman Sachs combines Masco's three-year financial targets with segment strategy to evaluate how premiumization in plumbing and commercial projects, expansion in wellness categories, growth in Behr and adjacent paint categories, operating cost savings, and shareholder returns contribute to valuation and EPS growth.

Methodology notes

  • equity_research12-month target price valuation

    13.0x Q5-Q8 adjusted EBITDA

    Goldman Sachs' $90 12-month target price is based on a 13.0x Q5-Q8 adjusted EBITDA estimate, used to gauge Masco's future earnings potential and valuation re-rating potential.

  • factor_analysisGS Factor Profile

    Growth, Financial Returns, Multiple, and Integrated percentile rankings

    Goldman Sachs Factor Profile compares the stock against the broader market and the industry coverage universe on a percentile basis. Masco ranks very highly on financial returns, but lower on growth, leaving its composite percentile around the middle.

  • event_analysisInvestor Day target decomposition

    Three-year revenue, margin, EPS, and capital allocation targets

    The report analyzes how product innovation, channel expansion, operational efficiency, and capital returns jointly drive earnings growth through 2028 based on the three-year targets disclosed at management's Investor Day.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

  • Masco Corp. common equity (MAS.US)
    Core coverage name; the report assigns a Buy rating and a 12-month $90 target price.
    Strengths
    Strong brand and channel advantages; plumbing, premium bath, Behr paint, and wellness businesses all have innovation and share-gain opportunities; cash generation supports buybacks, dividends, and tuck-in M&A.
    Weaknesses
    Growth factor ranking is relatively low, and the company remains highly sensitive to housing, repair/remodel activity, and consumer confidence; some equity metrics are less readable due to the balance sheet structure.
    Comparison
    Relative to the coverage universe and industry peers, Masco ranks very highly on financial returns but lower on growth, with its composite percentile around the middle.
    Risks
    Intensified competition, rising raw material costs, uncertainty in international production and sales, a slower-than-expected housing recovery, and failure to execute company-specific initiatives.

Key data

  • 12-month target price$90.00Based on a 13.0x Q5-Q8 adjusted EBITDA estimate.
  • Current price$67.48Price disclosed on the report cover.
  • Implied upside33.4%Calculated from the target price and current price disclosed in the report.
  • 2028 revenue target$8.1bn-$8.4bnEquivalent to 3% to 4% annual revenue growth.
  • 2028 adjusted EBIT margin target18%+Supported by volume/mix, cost savings, and price/cost improvement.
  • Adjusted EPS CAGR target through 2028about 10%Assumes a modest housing-market recovery and company-specific initiatives.
  • Capex target2.0%-2.5% of salesUsed to support organic growth and competitive advantages.
  • Dividend payout ratio targetabout 30%Part of the capital allocation framework.
  • Gross debt/EBITDA targetbelow 2.5xReflects management's leverage discipline.
  • 2028E EPS$5.15The forecast table shows EPS rising from $3.96 in 2025 to $5.15 in 2028E.
  • 2028E free cash flow yield7.6%The forecast table shows FCF yield rising from 6.0% in 2025 to 7.6% in 2028E.

Impact & implications

For investors, the implication of the report is that Masco's investment story is shifting from simply waiting for housing-cycle improvement to a compound-growth story driven by internal efficiency, innovation, and capital returns. If management can deliver on its 2028 targets and housing and consumer confidence recover modestly, the current valuation may be supported and the upside to the target price may be realized. However, if macro demand remains under pressure or execution falls short, margin expansion and EPS growth may be weakened.

Risks

  • If competitors intensify share capture efforts, Masco's growth and pricing power could be compressed.
  • The company may fail to execute planned initiatives such as innovation, cost savings, digitalization, and channel expansion.
  • Rising raw material costs that cannot be effectively passed through to customers could pressure margins.
  • Uncertainty in international production and sales could increase, including supply chain, regional demand, and geopolitical risks.
  • A slower-than-expected recovery in the housing market and consumer confidence could affect repair/remodel, DIY, and related building products demand.

What to watch

  • Quarterly progress toward the 2028 revenue, adjusted EBIT margin, and EPS CAGR targets.
  • Whether housing, repair/remodel, and new home starts begin a modest recovery starting in 2027.
  • Market share changes in the plumbing business across premium, commercial projects, and e-commerce channels.
  • Whether the wellness business can lift its global share from about 15% toward its 2030 target of 25%.
  • Growth performance of Behr in the Home Depot channel, among professional customers, and in one-stop adjacent categories.
  • Actual cost savings generated by the Masco Operating System, manufacturing network optimization, and automation investments.
  • The balance of capital allocation among buybacks, dividends, leverage, and tuck-in M&A.
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins